Sarepta Therapeutics has reported positive preliminary results from its Phase I/IIa clinical trial evaluating MYO-101 gene therapy for limb-girdle muscular dystrophy (LGMD) type 2E.

MYO-101 is designed to transduce skeletal and cardiac muscle with a gene coding for the full-length, native beta-SG protein. The absence of this protein is known to be responsible for LGMD2E.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The compound uses AAVrh74 vector that can be systemically delivered to skeletal, diaphragm and cardiac muscle.

LGMD2E is a muscular dystrophy that causes neuromuscular symptoms, such as difficulty in running, jumping and climbing stairs. Symptoms typically appear before the age of ten and the condition currently lacks a treatment or cure.

“Our gene therapy constructs have now produced high levels of expression of the missing protein of interest.”

Preliminary data from the first cohort of patients aged 4-13 years revealed robust transduced beta-SG expression when treated with a 5x13vg/kg infusion of MYO-101. The protein was observed to be properly localised to the muscle sarcolemma.

The results also demonstrated 47% mean fibre intensity, robust beta-SG quantification and a significant reduction in serum creatine kinase (CK) levels.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Sarepta Therapeutics president and CEO Doug Ingram said: “Our gene therapy constructs have now produced high levels of expression of the missing protein of interest, and strong results in related biomarkers, in Duchenne and LGMD2E, both cruel, fatal genetic diseases.

“And these results have potential read through to our other 4 LGMD programmes and further validate our gene therapy approach.”

Increased levels of liver enzymes were observed in two trial participants. One of the patients also experienced related transient rise in bilirubin and was designated as a serious adverse event (SAE).

Upon treatment with supplemental steroids, the elevated live enzymes returned to baseline.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact